An experimental drug targets the immune system in ALS, switching cells from 'attack' to 'protective' mode

Posted on Tuesday, June 15, 2010 - 13:37, By: Amy Madsen
Neuraltus Pharmaceuticals of Palo Alto, Calif., is developing a small molecule whose target is regulation of immune system cells believed to contribute to neuroinflammation and disease progression in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease). About ALS mechanisms